Double Medical Technology, Inc. Class A

As of June 30, 2026, Double Medical Technology, Inc. Class A carries a market capitalization of 17.30B, placing it among publicly traded companies globally. Its enterprise value stands at 15.94B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Double Medical Technology, Inc. Class A's next confirmed earnings release is scheduled for October 26, 2026.

As of June 30, 2026, Double Medical Technology, Inc. Class A has 414.02M shares outstanding.

As of June 30, 2026, Double Medical Technology, Inc. Class A trades at a trailing price-to-earnings ratio of 25.42. The price-to-sales ratio is 6.25, and the price-to-book ratio stands at 4.92.

As of June 30, 2026, Double Medical Technology, Inc. Class A trades at an EV/EBITDA multiple of 19.22 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 5.85 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 19.22 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 15.94B versus a market cap of 17.30B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Double Medical Technology, Inc. Class A maintains a current ratio of 3.02, meaning it holds 3.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 11.65, indicating elevated leverage, while an interest coverage ratio of 154.44 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Double Medical Technology, Inc. Class A posted a return on equity (ROE) of 19.95, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 18.42 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 13.95, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 16.40, useful for judging operating efficiency across full business cycles. The company generates approximately 585,461.78 in revenue per employee across its workforce of 4,653.75, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.59 indicates how many times Double Medical Technology, Inc. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Double Medical Technology, Inc. Class A recorded 110.77M in income tax expense. That works out to an effective tax rate of 13.47, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 822.04M, leaving 669.47M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 23, 2026, Double Medical Technology, Inc. Class A's stock has declined approximately 24.29% over the past 52 weeks. The 50-day moving average sits at 41.56, while the 200-day moving average is 44.04.

Over the twelve months ended June 30, 2026, Double Medical Technology, Inc. Class A generated 2.72B in revenue and converted that into 669.47M in net income, yielding earnings per share of 1.74. EBITDA reached 829.43M, while operating income came in at 811.82M.

As of June 30, 2026, Double Medical Technology, Inc. Class A holds 1.86B in cash and equivalents against 419.03M in total debt, resulting in a net debt position of -735.48M. Total book value stands at 3.52B, with working capital of 2.39B providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Double Medical Technology, Inc. Class A posted a gross margin of 72.34, reflecting its pricing power and cost economics. The operating margin of 29.80 and net profit margin of 24.57 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Double Medical Technology, Inc. Class A paid dividends of 0.53 per share. The dividend payout ratio of 28.43 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 2.24, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Double Medical Technology, Inc. Class A shareholders.

As of June 30, 2026, Double Medical Technology, Inc. Class A has an Altman Z-Score of 9.01, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.